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INTER PARTES REVIEW:
AN EARLY LOOK AT THE NUMBERS
Brian J. Love*
Shawn Ambwani**
81 University of Chicago Law Review Dialogue (forthcoming Oct. 2014)
In the roughly two years since inter partes review replaced inter partes
reexamination, petitioners have filed almost two-thousand requests for the
Patent Trial and Appeal Board to review the validity of issued U.S.
patents. 1 As partial data on inter partes review (IPR) has trickled out via
the blogosphere, 2 interest from patent practitioners and judges has grown
to a fever (and sometimes fevered) pitch. 3 To date, however, no
commentator has collected a comprehensive set of statistics on IPR.
*

Assistant Professor of Law and Co-Director of the High Tech Law Institute, Santa
Clara University School of Law.
**
Chief Operating Officer, Unified Patents, Inc., and Chairman, Licensing
Executives Society, Inc., High Tech Sector. We thank participants at the 2014 I.P.
Scholars Conference at U.C. Berkeley School of Law. Jacob Vigil and Alexander Shei
provided excellent research assistance.
1
The Patent Trial and Appeal Board began accepting petitions for inter partes review
on September 16, 2012. See Leahy-Smith America Invents Act, Pub. L. No. 112-29,
125 Stat. 284, 304 (2011) (stating that the sections pertaining to inter partes review
“shall take effect upon the expiration of the 1-year period beginning on the date of the
enactment”).
2
See, e.g., Post of Scott A. McKeown to Patents Post-Grant Blog, PTAB Institution
Rate Dips Into 60% Range, http://www.patentspostgrant.com/ptab-institution-rate-dipsinto-60-range (July 21, 2014); Post of Michelle Carniaux & Michael E. Sander to the
Inter Partes Review Blog, Instituted Patent Claims Survive in About One Third of All
IPR Trials, http://interpartesreviewblog.com/instituted-patent-claims-survive-one-thirdipr-trials/#more-662 (Aug. 13, 2014); Merchant & Gould, Inter Partes Review
Procedure
Statistics,
http://www.merchantgould.com/OurPractice_PostGrant_IPR_
Statistics.aspx (last updated Oct. 1, 2013).
3
See, e.g., Tony Dutra, Rader Regrets CLS Bank Impasse, Comments on Latest
Patent Reform Bill, Bloomberg BNA, Oct. 29, 2013, http://www.bna.com/rader-regretscls-n17179879684/ (“[T]he PTAB . . . [is] 300 administrative patent judges ‘acting as
death squads, killing property rights. ’” (quoting Randall Rader, then Chief Judge of the
U.S. Court of Appeal for the Federal Circuit)); Post of Robert Greene Sterne & Gene
Quinn to the IPWatchdog Blog, PTAB Death Squads: Are All Commercially Viable
Patents Invalid?, http://www.ipwatchdog.com/2014/03/24/ptab-death-squads-are-allcommercially-viable-patents-invalid/id= 48642/ (March 2014 1:42 PM) (“Ultimately, if
the PTAB continues on this path, the raison d’etre of the Patent Office and the entire
patent system will be called into question . . . .”).
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Moreover, what little data currently exists focuses on overall institution
and invalidation rates—data that, alone, gives us little idea whether IPR is
thus far accomplishing its original goal of serving as a quick, efficient
alternative to defending patent suits filed in federal court, particularly
those initiated by non-practicing entities (NPEs). 4
This Essay aims to fill both gaps by reporting the findings of an
empirical study tracking the outcome of IPRs and their impact on copending litigation. As described in greater detail below, we find that:
 Petitions for IPR are instituted for at least one challenged claim 84
percent of the time;
 Among instituted IPRs, all challenged claims are instituted 74
percent of the time;
 Among IPRs that reach a final decision on the merits, all instituted
claims are invalidated or disclaimed more than 77 percent of the
time;
 IPRs challenging NPE-owned patents are more likely to be
instituted and, on average, are instituted for a larger share of
challenged claims, but have their claims invalidated at a lower rate;
 Litigation proceeding in parallel with an instituted IPR is stayed
about 82 percent of the time.
Though it is too early to draw sweeping conclusions from these
statistics, they suggest that inter partes review promises to be considerably
more potent than inter partes reexamination and, moreover, to have a
substantial impact on co-pending patent litigation, particularly suits filed
by NPEs.
BACKGROUND
Prior to the America Invents Act, parties could administratively
challenge issued patents at the U.S. Patent and Trademark Office via one
4

H.R. Rep. No. 112-98, pt. 1, at 48 (2011) (referring to the post-grant review
proceedings created by the AIA as “quick and cost effective alternatives to litigation”);
see also Alston & Bird, LLP, Inter Partes Review – One Year Later 1 (Sept. 17, 2013)
(“IPR was designed to be a cost-effective alternative to litigation. In fact, its legislative
history states that the IPR process ‘will allow invalid patents that were mistakenly issued
by the USPTO to be fixed early in their life, before they disrupt an entire industry or
result in expensive litigation.’” (quoting 157 Cong. Rec. S1326 (daily ed. Mar. 7, 2011)
(statement
of
Sen.
Sessions))),
available
at
http://www.alston.com/
files/publication/ba36e481-8956-4318-a846-b1547e87b773/presentation/publication
attachment/651fa1eb-2994-427d-863e-b9275e537113/13-691-inter-partes-review-oneyear-laterpdf.pdf.
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of two forms of reexamination: ex parte reexamination, which proceeded
essentially as an extension of the patent’s original ex parte examination,
and inter partes reexamination, which allowed the challenger to take an
adversarial role in the process in exchange for a waiver of its ability to reargue validity later in court. 5
Though originally developed to serve as a cost-effective alternative to
full-blown litigation, 6 reexaminations rarely did so. To the contrary,
reexamination developed a well-deserved reputation for lengthy delays, a
lack of decisive results, and a permissiveness for claim amendments that
led some in the patent bar to view reexamination more as a vehicle for
patentees to strengthen their patent rights post hoc than as a tool for
possible infringers to quickly and cheaply eliminate invalid claims without
resorting to litigation. 7
Spurred by (at least a perception of) widespread litigation abuse,
Congress passed the America Invents Act (AIA) in 2011. 8 Among other
5

See, e.g., RatnerPrestia, Ex Parte versus Inter Partes Reexamination, http://
www.rppostgrant.com/ComparisonCharts/index.html (last visited Aug. 17, 2014)
(highlighting the similarities and differences between ex parte and inter partes
reexamination).
6
See 145 Cong. Rec. H6929, H6944 (daily ed. Aug. 3, 1999) (statement of Rep.
Dana Rohrabacher) (“This title was an attempt . . . to further encourage potential
litigants to use the PTO as a [sic] avenue to resolve patentability issues without expanding
the process into one resembling courtroom proceedings.”).
7
Inter partes reexamination took 3 years on average, after which challenged patents
survived 69% of the time, generally with new claims added. Patent & Trademark Off.,
Inter
Parte
Reexamination
Filing
Data
(Sept.
30,
2013),
http://www.uspto.gov/patents/stats/inter_parte_historical_stats_roll_up_EOY2013.pdf
[hereinafter PTO IPX Data]. As a result, many patent lawyers viewed reexamination as
more likely to strengthen a patent than to weaken it. See, e.g., Kyle J. Trout & Thomas
C. Stuart, Managing Risk in The Age Of The Patent Troll (Part 2), WESTLAW J. INTELL.
PROP., Feb. 19, 2014, at 1 (“[R]e-examination proves to be a double-edged sword that
[often] necessitates taking a license on less favorable terms against . . . strengthened
reissued claims . . . .”). As evidence of this, consider that many litigation-minded
patentees voluntarily subject their patents to ex parte reexamination. See, e.g., Changes
To Implement the Supplemental Examination Provisions of the Leahy-Smith America
Invents Act and To Revise Reexamination Fees; Final Rule, 77 Fed. Reg. 48827 (2012)
(“[T]he Office estimates that it receives approximately 110 requests for ex parte
reexamination filed by patent owners annually.”).
8
Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011). On
the motivations behind passage of the AIA, particularly the modification to administrative
review, see, e.g., Q. Todd Dickinson, Exec. Dir., Am. Intell. Prop. L. Assoc.,
Testimony before the U. S. Senate Judiciary Committee hearing on Protecting Small
Businesses and Promoting Innovation by Limiting Patent Troll Abuse 3-6, 8 (Dec. 17,
2013) (recounting the debate leading up to the AIA and referring to “the assertion of
allegedly invalid or overbroad patents” as “the very abuse for which AIA post-grant
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changes, the AIA replaced the existing regime of inter partes
reexamination with a modified and renamed inter partes review. 9 The
new legislation raised the bar for granting requests to review a patent, but
advantaged accepted petitions by mandating a shorter time-to-completion
and by allowing reviews to take place before the Patent Trial and Appeal
Board (PTAB) in the first instance, rather than on appeal. 10 These
modifications, legislators hoped, would transform inter partes
administrative patent challenges into the cheap, efficient litigation
alternative that inter partes reexamination never proved to be. 11
STUDY DESIGN
To test the extent to which Congress has thus far achieved its goals
with IPR, we collected a variety of data for every petition for inter partes
review filed between September 16, 2012—the effective date of the
statutory provision creating IPR—and March 31, 2014. 12 During this
period, challengers filed a total of 979 petitions. 13 As shown below in
Table 1, this tally is roughly half the total number of requests for inter
partes reexamination filed over the course of the thirteen years prior. 14 As
of September 30, 2014, the PTAB has received a total of 1,841 petitions
for IPR, making the rate of inter partes review six times that for inter

procedures were created”), available at http://ipwatchdog.com/blog/dickinson-senatetestimony-12-17-2013.pdf.
9
Leahy-Smith America Invents Act, 125 Stat. at 299-305 (setting forth procedures
for inter partes review).
10
See, e.g., Justin A. Henrix & Robert F. Schaffer, Post Grant Proceedings of the
AIA Provide New Opportunities and Require Reconsideration of Old Patent Litigation
Strategies, MED. DEVICE, June 15, 2012 (describing the similarities and differences
between inter partes review and inter partes reexamination), available at
http://www.finnegan.com/resources/articles/articlesdetail.aspx?news= 598696f7-7eba4fcb-83b8-2369caa91dd3.
11
See Dickinson, supra note 8.
12
Because institution decisions are generally issued close to six months after petitions
are filed, see infra tbl.3, this study window includes the vast majority of IPRs that
received at least a preliminary ruling on their merits by the end of September 2014.
Moreover, all data presented in this Essay is current as of at least September 30, 2014.
13
To identify IPRs and access the docket for each, we used Docket Navigator,
http://www.docketnavigator.com. In all, 987 petitions for IPR were filed during our
study window, but we excluded eight petitions challenging design (rather than utility)
patents.
14
PTO IPX data, supra (showing that 1,919 petitions for inter partes reexamination
were filed between November 29, 1999 and September 11, 2012).
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partes reexamination. 15
Table 1: Quantity of Filings
Inter Partes
Reexamination

Inter Partes
Review

Total Petitions:

1919

1841

Petitions per Month:

12.5

75.1

For each IPR, we collected several pieces of information about the
petition, the patent, and the parties involved. First, we determined
whether or not the PTAB decided to grant, or “institute,” the IPR
petition. 16 We also determined whether the IPR was still pending or had
terminated. 17 If it was terminated, we noted how and when it terminated.
As shown below in Table 2, of the 979 petitions that fall within our study
window, over 40 percent are still pending before the PTAB. However,
less than one percent of these petitions are still awaiting an institution
decision, which confirms that our study window contains the lion share of
petitions which have, to date, received substantial attention from the
PTAB.

15

See Docket Navigator, http://www.docketnavigator.com.
Leahy-Smith America Invents Act, 125 Stat. at 300 (setting as the standard for the
“institution” of inter partes review whether “there is a reasonable likelihood that the
petitioner would prevail with respect to at least 1 of the claims challenged in the
petition”).
17
An IPR can terminate in one of four ways: settlement, a decision not to institute
the petition, a final written decision from the PTAB, and a request for adverse judgment
from the patentee.
16
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Table 2: IPRs by Outcome Type
Pending:

413 (42.2%)

No Institution Decision Yet:

4

Instituted:

409

Terminated:

566 (57.8%)

Not instituted:

191

On the merits:
Untimely or duplicative:
Settled

132
19

59
215

After Institution:

128

Before Institution:

87

Final Written Decision or
Req. for Adv. Judgment

160

Next, we determined whether or not the respondent in the IPR was a
non-practicing entity. 20 Finally, we classified the challenged patent by
technology21 and determined whether or not it had ever been asserted in
19

A party seeking IPR of a patent asserted against it in court must, by statute, file a
petition within one year of being sued. 35 U.S.C. § 315(b) (“An inter partes review may
not be instituted if the petition requesting the proceeding is filed more than 1 year after
the date on which the petitioner, real party in interest, or privy of the petitioner is served
with a complaint alleging infringement of the patent. ”). If it fails to seek IPR within that
one-year window, its petition will be denied as untimely. The PTAB also may deny a
petition without reaching its merits on the grounds that it is substantially duplicative of an
earlier-filed petition. 35 U.S.C. § 325(d) (“In determining whether to institute or order a
proceeding . . . the Director may take into account whether, and reject the petition or
request because, the same or substantially the same prior art or arguments previously
were presented to the Office.”).
20
Non-practicing entities—patent owners that do not commercialize the patent
technology and thus, in patent parlance, do not “practice” their patent rights—can take
many forms, including for-profit firms engaged in patent monetization, individuals, and
universities. See, e.g., John R. Allison, et al., Extreme Value or Trolls on Top? The
Characteristics of the Most-Litigated Patents, 158 U. PA. L. REV. 1, 10-11 (2009)
(introducing a taxonomy of NPEs that includes – in addition to “patent assertion entities” –
universities, pre-product startups, and IP-holding subsidiaries of product-producing parent
companies). To classify patentees, we combined information obtained from public
records (namely, court and SEC filings), the patentees’ own websites, and business
directories available from third-parties like Hoover’s, Inc. and Bloomberg, L.P.
21
We categorized patents as one of the following categories: high-tech, bio-pharma,
other chemical, medical device, other mechanical, and other miscellaneous. See Brian J.
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court. 22 When we found co-pending litigation between the IPR petitioner
and respondent, we checked to see whether a motion to stay had been filed
in the suit and, if so, when it was filed and whether it was successful. 23
F INDINGS
In the paragraphs that follow, we provide statistics on various aspects
of inter partes review, including the duration of review, institution rates,
claim validity decisions, and impact on co-pending litigation. On the
whole, what we find suggests that inter partes review is considerably more
powerful than inter partes reexamination and, accordingly, more likely to
serve its intended purpose as an alternative to full-blown litigation. 24
First, we find that IPRs have thus far concluded within a relatively
short period of time. As shown below in Table 3, among all terminated
IPRs, the average time to termination was roughly nine months. Among
just those IPRs that reached a final determination, the average pendency
was roughly fifteen months—a duration still considerably shorter than the
thirty-six month average pendency of inter partes reexamination. 25 IPR
settlements, on average, occurred after seven months, and decisions not to
institute came, on average, a little under six months after the petition was
filed.

Love, An Empirical Study of Patent Litigation Timing: Could A Patent Term Reduction
Decimate Trolls Without Harming Innovators?, 161 U. PA. L. REV. 1309, 1329 (2013)
(describing broad definitions for “software,” “high-tech,” “medical device,”
“pharmaceutical,” and “biotechnology” patents). To make the most of limited data,
below we have consolidated these six classifications into four: high-tech, bio-pharmachemical, medical device-mechanical, and other.
22
We determined whether co-pending litigation existed by searching Lex Machina,
https://lexmachina.com/, for each challenged patent’s number.
23
We collected data on motions to stay by reviewing the docket sheet available on
Lex Machina for each co-pending suit.
24
A direct comparison of statistics for inter partes review and inter partes
reexamination is included below in Appendix B.
25
See PTO IPX data, supra note 7.
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Table 3: IPR Duration
Duration (days)
All Terminated IPRs:26

270

Not instituted:

169

Settled

221

Final Written Decision or
Req. for Adv. Judgment

456

Next, among IPRs with an institution decision, we find that petitioners
have thus far been quite successful in convincing the PTAB that
challenged patents deserve scrutiny. As shown below in Table 4, among
IPRs for which an institution decision was made on the petition’s merits,
the PTAB exercised its discretion to institute review of at least one
petitioned claim 84 percent of the time. Though this is lower than the
historical rate of acceptance for inter partes reexamination—93 percent—it
is nonetheless unexpectedly close. 27 In fact, 22 of the 132 IPRs that were
not instituted following a decision on the merits were petitions to review
patents for which another IPR was instituted. Taking this fact into
account, less than 14 percent of petitions both sought to challenge a unique
patent and were not instituted.
In addition, when PTAB panels have decided to institute inter partes
review, they have generally concluded that review is warranted for all
claims challenged in the petition. Among instituted IPRs, the PTAB
instituted review of all challenged claims 74 percent of the time and,
overall, instituted review of more than 88 percent of all challenged claims.
Moreover, as shown below in Table 5, despite the fact that almost
two-thirds of IPRs challenge a patent covering a computer- and
telecommunications-related invention, institution rates are quite consistent
across technologies. Appendix A includes more data broken down by
technology classification.

26

Excluding IPRs not instituted as untimely or duplicative.
See PTO IPX data, supra note 7 (reporting that 93% of requests for inter partes
reexamination were granted by the PTO’s central reexamination unit); Sterne & Quinn,
supra note 3 (“[N]o one could have predicted . . . how broadly and rapidly the new
challenges to the patentability of issued U.S. patents would become the standard defense
tactic in U.S. patent litigation in all areas of technology . . . . Approximately 80% of the
claims challenged in petitions are instituted for trial on at least one proposed ground of
unpatentability . . . .”).
27
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Table 4: Institution Rates
82328

Petitions with an institution decision:
Percent of IPRs with at least 1 claim
instituted:
Percent of IPRs with at least 1 claim
of a unique patent instituted:

84.0%
86.3%

Instituted IPRs:

691

Percent of IPRs will all challenged
claims instituted

74.0%

Percent of challenged claims instituted

88.3%

Table 5: By Tech Classification
High-Tech.

Bio./Pharma./Chem.

Med. Device/Mech.

Share of All Petitions (Total
No.)29

67.1% (657)

11.3% (111)

18.2% (178)

Petitions with an institution
decision:

551

95

149

83.8%

83.2%

82.6%

462

79

123

73.4%

74.7%

75.6%

86.5%

90.2%

92.9%

Percent of IPRs with at
least 1 claim instituted:
Instituted IPRs:
Percent of IPRs will all
challenged claims instituted
Percent of challenged
claims instituted

28

In six IPRs, the patentee requested an adverse judgment that was granted prior to
an institution decision.
29
Compare with PTO IPX Data, supra note 7 (reporting that 45% of inter partes
reexaminations challenged a patent directed to an “electrical” invention, 15% directed to
a “chemical” invention, and 25% to a “mechanical” invention). Some “high-tech”
patents can be challenged in an IPR or the “Transitional Program for Covered Business
Method Patents” (CBM review), see Post of Scott A. McKeown to Patents Post-Grant
Blog,
Where
Are
All
the
Business
Method
Patent
Challenges?,
http://www.patentspostgrant.com/where-are-all-the-business-method-patent-challenges
(Apr. 24, 2013) (discussing the tradeoffs between IPR and CBM review), which like IPR
was created by the AIA and went into effect in 2012, see AIA § 18. Thus, were it not
for the existence of CBM review, the share of patents challenged in IPRs that cover
“high tech” inventions might be larger still.

10
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Narrowing our focus further to IPRs with a decision on claim validity,
we find that petitioners have also been quite successful before the PTAB
on the merits of their challenges. As shown below in Table 6, among
instituted IPRs with a final decision on the merits, the PTAB eliminated all
instituted claims almost 78 percent of the time. Among the same group,
the PTAB eliminated all claims challenged in the petition 65 percent of the
time, giving petitioners a complete victory almost two-thirds of the time
they pursued their IPRs to a final decision.
Unlike acceptance rates, which are similar for both inter partes review
and reexamination, the rate at which petitioners succeed on the merits of
their petitions is markedly different: inter partes reexaminations ended in
complete victory for the petitioner just 31 percent of the time, less than
half as often. Moreover, over 60 percent of inter partes reexaminations
ended with patentees securing new, amended claims. 30 To date, the PTAB
has granted just a single motion to amend—one that was both unopposed
and filed by the U.S. itself. 31
Table 6: Claim Invalidation Rates
IPRs with decision on merits:
All instituted claims invalid or
disclaimed
All challenged claims invalid or
disclaimed
Motion to amend granted

160
77.5%
65%
0.62%

Moreover, as rough as IPR has been for patentees to date, we find that
it has been even tougher on non-practicing patentees. Table 7 below
compares petitions challenging patents owned by NPEs and product30

See PTO IPX Data, supra note 7 (reporting that in 61% of completed inter partes
reexaminations the challenged patent survived with claim amendments).
31
International Flavors & Fragrances Inc. v. U.S. Department of Agriculture, No.
IPR2013-00124, Paper No. 12 (P.T.A.B. May 20, 2014), available at
http://patentdocs.typepad.com/files/intl-flavors-fragrances-inc.-v.-u.s.a.-ipr2013-00124paper-12-p.t.a.b.-may-20-2014.pdf; see also Post of Scott A. McKeown to Patents PostGrant
Blog,
PTAB
Grants
First
Motion
to
Amend
in
IPR,
http://www.patentspostgrant.com/ptab-grants-first-motion-to-amend-in-ipr
(May 22,
2014) (“[T]he motion was unopposed, and was essentially a settlement by amendment
(challenger was satisfied that new claims were no longer a threat and simply walked
away) . . . .”).
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producing companies. Overall, NPEs are respondents in about 48 percent
of IPRs, a percentage that roughly matches the share of patent litigation
filed by NPEs. 32 By comparison to challenged patents owned by productproducing companies, patents owned by NPEs are more likely to be
challenged in an IPR that is instituted for at least one claim and, on
average, have a higher percentage of challenged claims instituted. That
said, in final decisions, NPE claims are less likely to be invalidated or
disclaimed, a finding that roughly cancels out NPEs’ greater per-claim
institution rate. Ultimately it would seem that, in the PTAB’s estimation
to date, NPE-owned patents are more likely than product-company-owned
patents to have suspect claims—but suspect claims in both types of patents
are roughly equally likely to be deemed invalid.
Table 7: NPEs v. Product-Producing Companies
NPEs

Prod. Cos.

Share of all IPRs:

48.3%

51.7%

Institution Rate:

88.7%

80%*

Among instituted IPRs, share instituting all
challenged claims

77.0%

71.1%

Among instituted IPRs, share of claims
instituted

90.8%

86.3%*

Among IPRs with decision on the merits,
share invalidating all instituted claims

75.3%

78.1%
* p < 0.01

Finally, turning to petitions pending alongside litigation in federal
court, we find that IPR has thus far proven to be a successful means for
accused infringers to halt patent suits filed against them. Table 8 below
shows data for IPRs with parallel litigation. Overall, in 80 percent of
32

See Sara Jeruss et al., The America Invents Act 500: Effects of Patent Monetization
Entities on US Litigation, 11 DUKE L. & TECH. REV. 357, 365, 377 (2012) (finding, in a
study of 100 patent suits filed each year from 2007 to 2011, that the percentage
attributable to NPEs was roughly 22% in 2007, 27% in 2008, 33% in 2009, 30% in
2010, and 40% in 2011); Robin Feldman et al., The AIA 500 Expanded: The Effects of
Patent Monetization Entities, UCLA J.L. & TECH., at *9, *55 (forthcoming) (expanding
their prior study to find that NPEs filed roughly 59% of patent suits in 2012);
Christopher A. Cotropia et al., Unpacking Patent Assertion Entities, MINN. L. REV., at
*25 (forthcoming) (finding that NPEs filed roughly 50% of patent infringement claims in
2010 and 2012), available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=
2346381.
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IPRs, the challenged patent was also asserted in litigation between the
petitioner and respondent. 33 Of patent suits proceeding in parallel with an
instituted IPR between the same parties, a motion to stay was filed in over
76 percent. Overall, these cases were stayed (at least in part) 82 percent
of the time, though rates varied considerably across districts. When a
motion to stay was filed before Markman briefing, cases were stayed even
more often: close to 84 percent of the time. Compared to inter partes
reexamination—for which district courts stayed co-pending litigation less
than half the time34—petitioning for inter partes review is much more
likely to result in a stay of litigation and, thereby, save litigation costs and
reduce a non-practicing patentees’ hold-up power. 35

33

By comparison, almost 76% of inter partes reexaminations challenged a litigated
patent. See PTO IPX Data, supra note 7.
34
See Eric J. Rogers, Ten Years of Inter Partes Patent Reexamination Appeals: An
Empirical View, 29 SANTA CLARA COMP. & HIGH TECH. L.J. 305, 320-21 (2012),
available
at
http://digitalcommons.law.scu.edu/cgi/viewcontent.cgi?article= 1559&
context= chtlj (collecting sources and concluding that overall “[m]otions to stay patent
litigation until the conclusion of a reexam are granted about half of the time” and also
that rates varied by district with the Northern District of California and the Eastern
District of Texas granting motions more and less than average, respectively).
35
Because non-practicing patentees do not sell products of their own, they cannot be
countersued for infringement and, thus, can impose asymmetrical litigation costs on their
opponents. See, e.g., Brian J. Love, Testimony before the California Assembly Select
Committee on High Technology informational hearing on Patent Assertion Entities (Oct.
30, 2013), available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id= 2347138.
As a result of this cost differential, NPEs can collect settlements that reflect the cost of
defense in addition to the value of the patented invention and strength of the patentee’s
claims. Id. If the cost of defense is large enough, patent litigation may still be lucrative
even when the patent-in-suit is weak and covers technology of little importance. Id.
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Table 8: Co-Pending Litigation Stays

Suits co-pending an instituted IPR
No. with a motion to stay:

36

No. with a decided motion: 37
% granted:

38

No. with a decided motion
filed before claim construction
briefing
% granted:

Overall

D. Del.

N.D. Cal.

E.D. Tex.

C.D. Cal.

249

48

31

32

11

190

36

26

19

9

171

32

25

16

9

81.9%

81.2%

80%

56.2%

77.8%

140

24

18

13

8

83.6%

83.3%

77.8%

69.2%

87.5%

In fact, the relative filing dates of IPR petitions and co-pending patent
suits suggests that administratively challenging a patent may also tend to
reduce the number of times that patent will be asserted in the future.
Among co-pending suits enforcing a patent challenged in a terminated
IPR, roughly 85 percent were filed prior to the IPR petition. 39 In addition,
over 10 percent of patents challenged in terminated IPRs have, to date,
never been asserted in court. In short, IPR does not seem to encourage
additional patent litigation and, for a substantial number of patents, it
appears to act as a complete substitute for litigation.
That said, it is still too early to draw a firm conclusion about IPR’s
impact on the final outcome of co-pending patent suits between the
petitioner and respondent. The vast majority of suits running in parallel
with an IPR decided on the merits have, themselves, not yet terminated.
Suits pending with IPRs invalidating claims of the asserted patent largely
remain stayed pending appeal of the PTAB’s decision to the Federal
36

In some suits, parties filed multiple motions to stay. This row reports the
percentage of suits with at least one motion.
37
In most instances, the motion was not ruled upon because the case settled, or was
stayed for a reason unrelated to inter partes review, before the court ruled on the motion.
In a small number of ongoing cases, motions to stay remained pending at the time of
publication.
38
This row reports the percentage of suits in which at least one motion to stay was
granted at least in part. Compare Wolf Greenfield, IP Strategy: Stays, Presentation to the
AIPLA Post Grant Committee (June 12, 2014) (copy on file with the authors) (finding, in
a sample that includes motions to stay filed prior to institution, a grant rate of 60% in the
District of Delaware, 83% in the Northern District of California, and 58% in the Eastern
District of Texas).
39
In suits between the petitioner and respondent, 94% of co-pending suits were filed
prior to the IPR petition. Among suits between the respondent and third-parties, about
80% of suits were filed first.
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Circuit, and suits pending with IPRs that were not instituted are largely
open and ongoing. 40 Thus, the true extent to which IPR simplifies patent
litigation remains to be seen.
*

*

*

Though it would be premature to make sweeping claims about inter
partes review at this time, so far IPR appears to be a powerful shield for
those accused of patent infringement (and those who anticipate they may
soon be). Compared to requests for inter partes reexamination, petitions
for inter partes review are currently granted at a similar rate, but once
instituted result in the elimination of every challenged claim about twice as
often, reach a final decision almost twice as quickly, and make accused
infringers almost twice as likely to win motions to stay co-pending
litigation. In its attempt to create a formidable avenue for administratively
challenging issued patents, Congress appears to have hit the mark—but
only time will tell for sure.

40

Though many final decisions remain pending on appeal, history suggests that the
affirmance rate is likely to be high. See Rogers, Ten Years of Inter Partes Patent
Reexamination Appeals: An Empirical View, supra note 34, at 342-43 (noting that in 19
appeals of inter partes reexamination to the Federal Circuit, the court dismissed 14 and
affirmed 5).

Appendix A: IPR Data by NPE Status and Tech Classification
Overall
Share of all IPRs (no.):

NPEs

Prod. Cos.
51.7% (506)

High Tech

Bio./Pharma./Chem.

Med. Device/Mech.

Other

100% (979)

48.3% (473)

67.1% (657)

11.3% (111)

18.2% (178)

3.4% (33)

Institution rate (no.):

84.0% (691/823)

88.7% (331/373)

80% (360/450)*

83.8% (462/551)

83.2% (79/95)

82.6% (123/149)

96.4% (27/28)

Among instituted IPRs,
share instituting all
challenged claims (no.)

74.0% (511/691)

77.0% (255/331)

71.1% (256/360)

73.4% (339/462)

74.7% (59/79)

75.6% (93/123)

74.1% (20/27)

Among instituted IPRs,
share of claims
instituted (no.)

88.3% (9769/11059)

90.8% (4559/5020)

86.3% (5210/6039)*

86.5% (6339/7325)

90.2% (1185/1313)

92.9% (1742/1875)

92.1% (503/546)

Among IPRs with
decision on the merits,
share invalidating all
instituted claims (no.)

77.5% (124/160)

75.3% (64/84)

78.1% (60/76)

72% (72/100)

87.0% (20/23)

93.1% (27/29)

62.5% (5/8)

Stay rate in suits copending instituted IPRs
(no. suits w/ a decided
motion)

81.9% (171)

85.5% (90)

77.8% (81)

82.9% (105)

58.3% (12)

85.7% (42)

83.3% (12)

* p < 0.01

Appendix B: IPX vs. IPR
Inter Partes
Reexamination

Inter Partes
Review

Total Petitions, as of Sept. 30,
2014:

1919

1841

Petitions per Month:

12.5

75.1

Average Duration to Final Decision
(months)

36.0

14.9

Electrical:

45.1%

67.1%

Chemical:

14.9%

11.3%

Mechanical:

25.5%

18.2%

Institution Rate

93.4%

84.0%

All (Instituted) Claims Invalidated

31.5%

78.8%

Amended Claims Added

60.9%

0.62%

Percent with Co-Pending Litigation

75.5%

78.8%

Grant Rate for Motions to Stay

~50%

81.9%

Tech Breakdown:

